- Home
- ONON vs GMAB Comparison
ONON vs GMAB Comparison
Compare ONON & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONON
- GMAB
- Stock Information
- Founded
- ONON 2010
- GMAB 1999
- Country
- ONON Switzerland
- GMAB Denmark
- Employees
- ONON N/A
- GMAB N/A
- Industry
- ONON Shoe Manufacturing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ONON Consumer Discretionary
- GMAB Health Care
- Exchange
- ONON Nasdaq
- GMAB Nasdaq
- Market Cap
- ONON 14.8B
- GMAB 15.0B
- IPO Year
- ONON 2021
- GMAB N/A
- Fundamental
- Price
- ONON $54.79
- GMAB $20.14
- Analyst Decision
- ONON Strong Buy
- GMAB Buy
- Analyst Count
- ONON 24
- GMAB 8
- Target Price
- ONON $54.70
- GMAB $43.00
- AVG Volume (30 Days)
- ONON 3.0M
- GMAB 1.1M
- Earning Date
- ONON 11-12-2024
- GMAB 02-12-2025
- Dividend Yield
- ONON N/A
- GMAB N/A
- EPS Growth
- ONON 55.69
- GMAB 14.35
- EPS
- ONON 0.46
- GMAB 10.80
- Revenue
- ONON $2,555,669,993.00
- GMAB $2,967,926,227.00
- Revenue This Year
- ONON $31.08
- GMAB $30.31
- Revenue Next Year
- ONON $27.46
- GMAB $16.49
- P/E Ratio
- ONON $119.88
- GMAB $18.15
- Revenue Growth
- ONON 26.12
- GMAB 17.75
- 52 Week Low
- ONON $25.78
- GMAB $19.85
- 52 Week High
- ONON $60.12
- GMAB $32.88
- Technical
- Relative Strength Index (RSI)
- ONON 46.75
- GMAB 32.84
- Support Level
- ONON $56.53
- GMAB $19.85
- Resistance Level
- ONON $58.93
- GMAB $22.33
- Average True Range (ATR)
- ONON 1.85
- GMAB 0.36
- MACD
- ONON -0.52
- GMAB -0.10
- Stochastic Oscillator
- ONON 5.16
- GMAB 11.69
About ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa, and Asia-Pacific region.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.